Yuhan Corporation
Seoul, South Korea
NCT Number: NCT01609907
The objective of this study is to compare pharmacokinetics after single oral administration of rosuvastatin and valsartan each separately versus coadministration of rosuvastatin and valsartan in healthy male volunteers.
Looking for future studies?
Notify Me20 year–50 year
Male
Interventional
Phase 1
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Time frame: 18 points up to Day 4
Time frame: 18 points up to Day 4
Time frame: 18 points up to Day 4
Time frame: 18 points up to Day 4
Time frame: 18 points up to Day 4
Time frame: 18 points up to Day 4
Time frame: 18 points up to Day 4
Time frame: 18 points up to Day 4
Time frame: 18 points up to Day 4
Time frame: 18 points up to Day 4
Time frame: 18 points up to Day 4
Time frame: 18 points up to Day 4
Time frame: 18 points up to Day 4
Looking for future studies?
Notify MeYuhan Corporation
Industry
A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan in Healthy Male Volunteer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02593032
Cardiovascular Diseases, Diabetes Mellitus
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07119658
Body Weight, Cardiovascular Diseases
Indianapolis, Indiana, United States
View Trial DetailsNCT01764178
Cardiovascular Diseases, Dyslipidemias
Seoul, South Korea
View Trial DetailsNCT06486532
Cardiovascular Diseases, Dyslipidemias
Saint Louis Park, Minnesota, United States
View Trial Details